Biosynex SA
PAR:ALBIO

Watchlist Manager
Biosynex SA Logo
Biosynex SA
PAR:ALBIO
Watchlist
Price: 2.77 EUR -3.82% Market Closed
Market Cap: 29.8m EUR
Have any thoughts about
Biosynex SA?
Write Note

Biosynex SA
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biosynex SA
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Biosynex SA
PAR:ALBIO
Depreciation & Amortization
€9.9m
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Edap Tms SA
NASDAQ:EDAP
Depreciation & Amortization
€1.9m
CAGR 3-Years
-3%
CAGR 5-Years
10%
CAGR 10-Years
5%
Biomerieux SA
PAR:BIM
Depreciation & Amortization
€233.9m
CAGR 3-Years
3%
CAGR 5-Years
5%
CAGR 10-Years
10%
Carmat SA
PAR:ALCAR
Depreciation & Amortization
€18.6m
CAGR 3-Years
1%
CAGR 5-Years
65%
CAGR 10-Years
37%
Visiomed Group SA
PAR:ALVMG
Depreciation & Amortization
€3.1m
CAGR 3-Years
N/A
CAGR 5-Years
32%
CAGR 10-Years
15%
Amplitude Surgical SA
PAR:AMPLI
Depreciation & Amortization
€11.2m
CAGR 3-Years
-15%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
No Stocks Found

Biosynex SA
Glance View

Market Cap
28.9m EUR
Industry
Health Care

Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.

ALBIO Intrinsic Value
7.73 EUR
Undervaluation 64%
Intrinsic Value
Price

See Also

What is Biosynex SA's Depreciation & Amortization?
Depreciation & Amortization
9.9m EUR

Based on the financial report for Jun 30, 2024, Biosynex SA's Depreciation & Amortization amounts to 9.9m EUR.

What is Biosynex SA's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
16%

Over the last year, the Depreciation & Amortization growth was -68%. The average annual Depreciation & Amortization growth rates for Biosynex SA have been 16% over the past three years .

Back to Top